EA201791455A1 - Способ лечения - Google Patents

Способ лечения

Info

Publication number
EA201791455A1
EA201791455A1 EA201791455A EA201791455A EA201791455A1 EA 201791455 A1 EA201791455 A1 EA 201791455A1 EA 201791455 A EA201791455 A EA 201791455A EA 201791455 A EA201791455 A EA 201791455A EA 201791455 A1 EA201791455 A1 EA 201791455A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
hfpef
pyridinone
pyridinyl
composition
Prior art date
Application number
EA201791455A
Other languages
English (en)
Inventor
Дэвид Кайе
Original Assignee
Кардиора Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014905194A external-priority patent/AU2014905194A0/en
Application filed by Кардиора Пти Лтд. filed Critical Кардиора Пти Лтд.
Publication of EA201791455A1 publication Critical patent/EA201791455A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к способам лечения пациентов с сердечной недостаточностью с сохраненной фракцией выброса (HFpEF) с помощью композиции с замедленным высвобождением кардиотонических соединений 5-(пиридинил)-2(1Н)-пиридинона.
EA201791455A 2014-12-22 2015-12-21 Способ лечения EA201791455A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014905194A AU2014905194A0 (en) 2014-12-22 Method of Treatment
PCT/AU2015/050820 WO2016101024A1 (en) 2014-12-22 2015-12-21 Method of treatment

Publications (1)

Publication Number Publication Date
EA201791455A1 true EA201791455A1 (ru) 2017-12-29

Family

ID=56148784

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791455A EA201791455A1 (ru) 2014-12-22 2015-12-21 Способ лечения

Country Status (13)

Country Link
US (2) US10493067B2 (ru)
EP (1) EP3236963B1 (ru)
JP (2) JP2018500365A (ru)
KR (1) KR20170098897A (ru)
CN (1) CN107530337B (ru)
AU (1) AU2015372434B2 (ru)
BR (1) BR112017013015A2 (ru)
CA (1) CA2971071A1 (ru)
EA (1) EA201791455A1 (ru)
IL (1) IL253028B (ru)
MX (1) MX2017008248A (ru)
SG (1) SG11201704980XA (ru)
WO (1) WO2016101024A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493067B2 (en) * 2014-12-22 2019-12-03 Cardiora Pty Ltd. Method of treating heart failure with preserved ejection fraction by administering milrinone
US11969422B2 (en) 2020-12-10 2024-04-30 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
US11730733B2 (en) 2020-12-10 2023-08-22 Imbria Pharmaceuticals, Inc. Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
US12076318B2 (en) 2020-12-10 2024-09-03 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
US11793807B2 (en) 2020-12-10 2023-10-24 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
WO2022125370A1 (en) * 2020-12-10 2022-06-16 Imbria Pharmaceuticals, Inc. Methods of treating heart conditions using modified forms of trimetazidine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297360A (en) 1980-03-28 1981-10-27 Sterling Drug Inc. 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use
US4313951A (en) 1979-11-26 1982-02-02 Sterling Drug Inc. 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor
NZ195564A (en) 1979-11-26 1983-09-30 Sterling Drug Inc 5-pyridinyl-2(1h)-pyridinones pharmaceutical compositions intermediate pyridine compounds
GB8414220D0 (en) 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5213811A (en) 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
DK0707475T3 (da) 1993-06-14 1997-12-29 Janssen Pharmaceutica Nv Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
GB9402203D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
EP1549296A4 (en) 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co METFORMIN FORMULATIONS WITH DELAYED RELEASE
KR100548925B1 (ko) 2002-10-23 2006-02-02 한미약품 주식회사 약물의 경구투여용 서방성 조성물
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CA2816448A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
KR20140039030A (ko) * 2011-06-29 2014-03-31 교토후고리츠다이가쿠호진 종양 부위의 식별 장치 및 식별 방법
CN104023725B (zh) * 2011-08-16 2019-04-26 卡迪欧拉有限公司 控释制剂
WO2013101830A1 (en) 2011-12-27 2013-07-04 Ironwood Pharmaceuticals, Inc. 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators
WO2013116194A2 (en) 2012-01-30 2013-08-08 O'connell Timothy D Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis
US10493067B2 (en) * 2014-12-22 2019-12-03 Cardiora Pty Ltd. Method of treating heart failure with preserved ejection fraction by administering milrinone

Also Published As

Publication number Publication date
JP2022163681A (ja) 2022-10-26
AU2015372434A1 (en) 2017-07-13
KR20170098897A (ko) 2017-08-30
SG11201704980XA (en) 2017-07-28
EP3236963A4 (en) 2018-08-08
WO2016101024A1 (en) 2016-06-30
AU2015372434B2 (en) 2018-10-04
JP2018500365A (ja) 2018-01-11
MX2017008248A (es) 2018-02-19
US10493067B2 (en) 2019-12-03
EP3236963B1 (en) 2020-01-29
CA2971071A1 (en) 2016-06-30
BR112017013015A2 (pt) 2018-03-06
NZ732954A (en) 2021-11-26
US20170348292A1 (en) 2017-12-07
US11291660B2 (en) 2022-04-05
US20200101053A1 (en) 2020-04-02
JP7475324B2 (ja) 2024-04-26
IL253028A0 (en) 2017-08-31
CN107530337A (zh) 2018-01-02
EP3236963A1 (en) 2017-11-01
CN107530337B (zh) 2021-07-09
IL253028B (en) 2019-12-31

Similar Documents

Publication Publication Date Title
HUS2400030I1 (hu) Aril, heteroaril és heterociklusos vegyületek komplement által közvetített rendellenességek kezelésére
EA201791455A1 (ru) Способ лечения
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
IL249988A0 (en) Process for preparing 3-(3-chloro-h1-pyrazol-1-yl)pyridine
IL250628A0 (en) Process for preparing 3-(3-chloro-h1-pyrazol-1-yl)pyridine
ZA201700243B (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
IL250984A0 (en) Process for preparing 3-(3-chloro-1h-pyrazol-1-yl)pyridine
IL247942A0 (en) Compositions and methods for drops in macular edema as a result of diabetes
ZA201700168B (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
DK3134084T3 (da) Fremgangsmåde til behandling af lungeadenokarcinom
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
EA201692534A1 (ru) Способы лечения гипотонии
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
IN2014MU00675A (ru)
EP3256137A4 (en) Method of treating heart failure
SG10202008024VA (en) Method for Treating Heart Failure
EP3481399A4 (en) METHOD FOR TREATING HEART INSUFFICIENCY
DK3423440T3 (da) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-on-derivat til behandlingen af hjernetumorer
DK3194653T3 (da) Kontinuerlig fremgangsmåde til behandling af lignocellulosisk biomasse
EP3165521A4 (en) Method of preparing dabigatran etexilate intermediate and intermediate compound
IL253055A0 (en) A method for the preparation of certain tetrazoles converted in positions 1 and 5